Bristol-Myers Squibb Company Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
Bristol-Myers Squibb Company Forecast
Bristol-Myers Squibb Company short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 36.6% a year, a typical one-standard-deviation range is 58.23–64.55 over a week, 54.91–67.87 over a month and 38.95–83.83 over a year. (Signals as of 1 Nov 2026.)
Bristol-Myers Squibb Company Price Chart
Bristol-Myers Squibb Company Factors
YoY −12.6%
YoY +28.4%
YoY +6.0%
YoY +20.9%
YoY +18.0%
YoY −54.6%
YoY +14.5%
YoY −23.4%
YoY +33.7%
YoY −6.7%
YoY −8.2%
YoY +25.3%
YoY +23.5%
YoY +53.8%
YoY −30.4%
YoY +16.7%
YoY +41.5%
Bristol-Myers Squibb Company fundamentals: income statement, balance sheet & cash flow
Bristol-Myers Squibb Company reported revenue of $48.20bn and net income of $7.05bn in FY2025, the year ended 31 December 2025 — revenue down 0.2% and net income up 178.8% on the prior year. Free cash flow was $12.85bn. These figures are as reported in the filings, not restated: 39 fiscal years and 159 quarters of history, back to December 1987. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 48.20 | 48.30 | 45.01 | 46.16 | 46.39 |
| Cost of revenue | 13.94 | 13.97 | 10.69 | 10.14 | 9.94 |
| Gross profit | 34.26 | 34.33 | 34.31 | 36.02 | 36.45 |
| Research & development | 9.95 | 11.16 | 9.30 | 9.51 | 10.20 |
| Selling, general & admin. | — | 17.29 | 16.82 | 17.41 | 17.71 |
| Operating income | 13.72 | 5.89 | 8.20 | 9.10 | 8.54 |
| EBITDA | 15.23 | 3.17 | 19.37 | 19.22 | 20.12 |
| Interest expense | 1.89 | 1.95 | 1.17 | 1.23 | 1.33 |
| Pre-tax income | 9.33 | -8.38 | 8.44 | 7.71 | 8.10 |
| Income tax | 2.27 | 0.55 | 0.40 | 1.37 | 1.08 |
| Net income | 7.05 | -8.95 | 8.03 | 6.33 | 6.99 |
Download Bristol-Myers Squibb Company fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BMY.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Bristol-Myers Squibb Company
Explore MacroFinance macro & markets research and analysis.
Bristol-Myers Squibb Company Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Bristol-Myers Squibb Company; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Bristol-Myers Squibb Company’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Bristol-Myers Squibb Company (United States)
Bristol-Myers Squibb Company is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Bloomsbury Publishing Plc
Frequently asked questions
What is Bristol-Myers Squibb Company?
What is the latest Bristol-Myers Squibb Company price?
Is Bristol-Myers Squibb Company in an uptrend?
How volatile is Bristol-Myers Squibb Company?
What factors affect Bristol-Myers Squibb Company?
Which trading strategies trade Bristol-Myers Squibb Company?
How are Bristol-Myers Squibb Company returns analysed?
Where can I download free Bristol-Myers Squibb Company historical data?
Free Bristol-Myers Squibb Company historical data (last 10 years)
Browse or instantly download the last 10 years of Bristol-Myers Squibb Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BMY.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 58.8 |
| 2026-11-19 | 58.34 |
| 2026-11-18 | 59.56 |
| 2026-11-17 | 61.35 |
| 2026-11-16 | 62.93 |
| 2026-11-13 | 63.43 |
| 2026-11-12 | 62.32 |
| 2026-11-11 | 62.91 |
| 2026-11-10 | 62.8 |
| 2026-11-09 | 62.14 |
About this stock
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.